文献速递炎症性肠病

炎症性肠病患者接受肿瘤坏死因子拮抗剂治疗后银屑病样疾病的发生率:一项全国性人群队列研究

Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2018-06-05

基于韩国国民健康保险理赔数据,2007至2016年共纳入50502例炎症性肠病患者,比较5428例使用抗肿瘤坏死因子(TNF)药物超过6个月者与10856例匹配对照。抗TNF组银屑病、掌跖脓疱病及银屑病关节炎风险均显著升高,其中掌跖脓疱病在男性和年轻患者中风险升高最明显。

要点

  • 抗TNF组银屑病发生率为36.8/万人年,对照组为14.5/万人年,HR 2.357(95%CI 1.668-3.331)。
  • 掌跖脓疱病HR 9.355(95%CI 2.754-31.780),银屑病关节炎HR 2.926(95%CI 1.640-5.218)。
  • 掌跖脓疱病风险在男性(HR 19.682)和10-39岁患者(HR 14.318)中显著升高。

核心结论

  • 炎症性肠病患者使用抗TNF药物后银屑病样疾病风险增加,其中掌跖脓疱病风险升高幅度最大,尤其在男性和年轻患者中。

研究设计与样本

  • 全国性人群队列研究,使用韩国国民健康保险理赔数据,2007至2016年共识别50502例炎症性肠病患者,比较5428例使用抗TNF药物超过6个月者与10856例匹配对照。

主要发现

  • 抗TNF组银屑病发生率为36.8/万人年,对照组为14.5/万人年,HR 2.357(95%CI 1.668-3.331)。
  • 抗TNF组掌跖脓疱病HR 9.355(95%CI 2.754-31.780),银屑病关节炎HR 2.926(95%CI 1.640-5.218)。
  • 克罗恩病亚组银屑病HR 2.549(95%CI 1.658-3.920),溃疡性结肠炎亚组HR 2.105(95%CI 1.155-3.836)。
  • 男性掌跖脓疱病HR 19.682(95%CI 3.867-100.169),10-39岁患者HR 14.318(95%CI 2.915-70.315);女性和≥40岁患者两组发生率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are increasing reports of paradoxical psoriasiform diseases secondary to anti-tumour necrosis factor (TNF) agents. AIMS: To determine the risks of paradoxical psoriasiform diseases secondary to anti-TNF agents in patients with inflammatory bowel disease (IBD). METHODS: A nationwide population study was performed using the Korea National Health Insurance Claim Data. A total of 50 502 patients with IBD were identified between 2007 and 2016. We compared 5428 patients who were treated with any anti-TNF agent for more than 6 months (anti-TNF group) and 10 856 matched controls who had never taken anti-TNF agents (control group). RESULTS: Incidence of psoriasis was significantly higher in the anti-TNF group (36.8 per 10 000 person-years) compared to the control group (14.5 per 10 000 person-years) (hazard ratio [HR] 2.357, 95% confidence interval [CI] 1.668-3.331). Palmoplantar pustulosis (HR 9.355, 95% CI 2.754-31.780) and psoriatic arthritis (HR 2.926, 95% CI 1.640-5.218) also showed higher risks in the anti-TNF group. In subgroup analyses, HRs for psoriasis by IBD subtype were 2.549 (95% CI 1.658-3.920) in Crohn's disease and 2.105 (95% CI 1.155-3.836) in ulcerative colitis. Interestingly, men and younger (10-39 years) patients have significantly higher risks of palmoplantar pustulosis (HR 19.682 [95% CI 3.867-100.169] and HR 14.318 [95% CI 2.915-70.315], respectively), whereas women and older (≥40 years) patients showed similar rates between the two groups. CONCLUSIONS: The risks of psoriasiform diseases are increased by anti-TNF agents in patients with IBD. Among psoriasiform diseases, the risk of palmoplantar pustulosis shows the biggest increase particularly in male and younger patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018. PMID: 29869804. doi:10.1111/apt.14822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。